NETEC COVID-19 Webinar Series

Monoclonal Antibody Therapeutics: How to Operationalize mAB Therapy at Your Facility

Release Date: 12/04/2020

Expires: 12/03/2021

The estimated time to complete this enduring material is 60 minutes.

TARGET AUDIENCE

This enduring material is intended primarily for healthcare workers and teams which may include but are not limited to, medical and nursing staff, administration, education/training leadership, and infection control leadership. Staff specializing in emergency management, communications, specialized clinical areas, laboratory, facilities management and environmental services are also welcome.

EDUCATIONAL OBJECTIVES

At the conclusion of this enduring material, the participant should be better able to:

• Identify important considerations involving Monoclonal Antibody Therapeutics available for emergency use authorization (EUAs) for mild-to-moderate COVID-19 cases
• Discuss recent criteria for the FDA approved investigational therapy for outpatient settings in determining qualifications based on risk stratification
• Summarize how to operationalize the use of Monoclonal Antibody Therapeutics when implementing this strategy within your organization as derived from case studies

FACULTY AND PLANNING COMMITTEE DISCLOSURES

The following faculty** and planning committee members have no financial relationships to disclose.

• Bryan Alexander, PharmD, BCIDP, AAHIVP**
• Sarah Anderson-Fiore, MPH, CHES
• Sonia Bell, BS
• Rebecca Duchman, MSN, MA, RN, NEA-BC**
• Heidi Keeler, PhD, RN
• Allison Klajbor, BS
• G. Marshall Lyon, III, MD, M.M.Sc, BS**
• Benjamin Mattson, MS Ed
• Jason Noble, BA, BFA
• Renee Paulin, MSN, RN, CWOCN
• Brenda Ram, CMP, CHCP
• Michelle Schwedhelm, MSN, RN, NEA-BC**
• Patricia Tennill, BSN, RN
• Sharon Vanairsdale, DNP, APRN, ACNS-BC, NP-C, CEN. FAEN, FAAN
• Sami Vasistha, MS

FINANCIAL SUPPORT

This program is funded by ASPR & CDC